Senetek terminates accord with Ardana

California, USA-based Senetek, a life sciences company engaged in the development of technologies that target the science of healthy aging, has announced termination of the license agreement for its erectile dysfunction product, Invicorp, with Ardana Bioscience of the UK. The agreement was a license to manufacture, market, sell and distribute Invicorp - an auto-injector which delivers 0.025mg of aviptadil and 1mg of phentolamine mesilate per dose - in Europe and was terminated following the company's contractual rights, precipitated by Ardana's entry into voluntary administration on June 27 (Marketletter July 7).

Frank Massino, Senetek's chief executive, stated: "we have advised Ardana of the Invicorp license termination and served demand for return of all related clinical and regulatory data. We have received a number of inquiries regarding the availability of the European license and we are confident this will be a valuable and productive asset in the hands of the right partner."

According to the US firm, Invicorp is expected to capture a significant share of the moderate-to-severe ED market and become the therapy of choice for second-line treatment. The product has received marketing authorization in Denmark as well as in England. Additionally, it has been approved in New Zealand. Senetek has entered into an exclusive licensing and collaborative marketing agreement for the commercialization of Invicorp with Plethora Solutions for the North American market.